ClinicalTrials.gg
RecruitingNCT04339907AH-TearsUpdated Oct 23, 2026

Inflammatory Mediators of Glaucoma After Corneal Transplantation (AH-Tears)

An interventional study of Sampling of tears and Sampling of aqueous humor in Glaucoma, Corneal Transplantation and Inflammation, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started May 2020; still recruiting 6 years 6 months later.
Updated Oct 23, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Glaucoma with a site in Canada — 17 open to participants now, 21 under way, 1 of them phase 3. Glaucoma · Canada.

Planned enrollment
12th of 68
200 · median 62
Started
2020
with 6 others
No phase
43 of 85
14 open now
Primary completion
2028-10
later than 18 of 20 live
Registered
66th of 85
by date
Lead sponsor
7 of 85
Centre hospitalier de l'Université de Montréal (CHUM)

Among the 85 studies in Glaucoma with a site in Canada, this one is the 12th largest by planned enrollment of the 68 interventional ones that give a count, is one of 7 that started in 2020, is one of 43 with no phase, reaches primary completion later than 18 of the 20 other live ones, and was the 66th registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

17 of the 85 studies in Glaucoma with a site in Canada are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Glaucoma with a site in Canada, or all of them as a file.
02

Study summary

Glaucoma is the most common threat to vision rehabilitation in patients with Boston keratoprosthesis type 1 (KPro) implantation. High intraocular pressure (IOP) is the most important risk factor for glaucoma and may lead to irreversible retinal and optic nerve damage. Glaucoma drainage device (GDD) surgery is used to divert aqueous humor (AH) from the anterior chamber to an external reservoir to regulate flow and decrease the IOP. The AH is in direct communication with any corneal damage or surgery undertaken in the anterior chamber and can serve as a source of potential biomarkers to detect early inflammatory or glaucomatous changes. Tears are also one of the most accessible and non-invasive source of biomarkers, especially in Kpro eyes where the central optic allows communication between aqueous humor and the tears at the surface of the eye. The investigators propose to test the hypothesis that distinct inflammatory mediators in the AH and tears can serve as biomarkers for glaucoma development and progression after CT, making them specifically amenable to targeted treatment strategies to minimize vision loss.

Read the detailed description

The only curative treatment for corneal diseases that progress to vision loss is corneal transplantation (CT). Penetrating keratoplasty (PK) involves the surgical replacement of the host cornea with a donor cornea. In cases of graft failure with standard PK, the Boston keratoprosthesis (KPro), the most common artificial cornea, can alternatively restore vision rapidly. A current limitation in the use of KPro is that the vast majority of patients are at high risk of developing glaucoma. Glaucoma contributes to significant ocular morbidity after CT surgery and is the leading cause of irreversible vision loss after CT. High intraocular pressure (IOP) is the most important risk factor for glaucoma and may lead to irreversible retinal and optic nerve damage. Glaucoma is treated using drops or surgery to reduce IOP. When IOP-lowering drugs and laser surgery fail, glaucoma drainage device (GDD) surgery is used to divert aqueous humor (AH) from the anterior chamber to an external reservoir to regulate flow and decrease the IOP. The cause and mechanisms of glaucoma development and progression following CT are still unknown. Neuroinflammation has been suggested to play a key role in glaucomatous damage following CT. The role of inflammatory biomarkers in glaucoma pathogenesis after CT remains poorly understood and must be further studied. The AH is in direct communication with any corneal damage or surgery undertaken in the anterior chamber and can serve as a source of potential biomarkers to detect inflammatory changes in glaucoma. Tears are also one of the most accessible and non-invasive source of biomarkers, especially in Kpro eyes where the central optic allows communication between AH and the tears at the surface of the eye. Full thickness corneal transplantation (penetrating keratoplasty and Boston KPro) and intraocular surgeries for glaucoma, cataract and retina that are required by the participants of the study offer the opportunity to have access to the AH and tears in an accessible and safe way, without additional risks. These samples of AH and tears will be analyzed for multiple inflammatory mediators simultaneously.

HYPOTHESIS:

The investigators propose to test the hypothesis that distinct inflammatory mediators in the AH and tears can serve as biomarkers for glaucoma development and progression after CT, making them specifically amenable to targeted treatment strategies to minimize vision loss.

OBJECTIVES:

  1. To examine the (a) presence and (b) concentration of inflammatory mediators in glaucoma after corneal transplantation.
  2. To examine the correlation between the presence and concentration of inflammatory mediators and clinical ophthalmological data.
  3. To examine the correlation between the inflammatory mediators found in aqueous humor and tears.
03

Conditions studied

  • Glaucoma
  • Corneal Transplantation
  • Inflammation

Keywords

  • Boston keratoprosthesis type 1
  • Glaucoma
  • Aqueous Humor
  • Tears
  • Inflammation
  • Penetrating keratoplasty
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years old or older
  • Ability to be followed for the duration of the study
  • Presence of ocular disease specified for each group

Specific criteria for each group:

  • Group 1 : have no glaucoma and no systemic diseases
  • Group 2 : need to have glaucoma filtration surgery without prior corneal transplantation
  • Group 3 : need to have corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis), with or without glaucoma
  • Group 4 : need to have intraocular surgery after prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis)
  • Group 5 : need to have glaucoma filtration surgery with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis)

Exclusion criteria

Exclusion Criteria:

  • Aged less than 18
  • Inability to give
  • Presence of ocular diseases other than those studied herein
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Sham comparator
    Cataract surgery only

    Participants needing cataract surgery, without glaucoma or any other corneal diseases.

    Other: Sampling of tears · Other: Sampling of aqueous humor

  • Sham comparator
    Glaucoma surgery only

    Participants needing glaucoma filtration surgery, without any prior corneal transplantation.

    Other: Sampling of tears · Other: Sampling of aqueous humor

  • Experimental
    Corneal transplantation

    Participants needing corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis), with or without glaucoma. This allows analyzing samples at baseline (time 0), at the time of the corneal transplantation procedure.

    Other: Sampling of tears · Other: Sampling of aqueous humor

  • Experimental
    Intraocular surgery following corneal transplantation

    Participants needing intraocular surgery (cataract, retina or glaucoma), with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis). This allows analyzing samples during the potential development or progression of glaucoma in participants who have previously undergone corneal transplantation.

    Other: Sampling of tears · Other: Sampling of aqueous humor

  • Experimental
    Glaucoma surgery following corneal transplantation

    Participants needing glaucoma filtration surgery, with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis). This allows analyzing samples once glaucoma is confirmed in participants who have previously undergone corneal transplantation.

    Other: Sampling of tears · Other: Sampling of aqueous humor

Interventions

  • OtherSampling of tears

    Tears will be collected at the start of any of surgery for which the participant presents. It will be collected using a tear-wash method to allow for protein collection. 0.06 ml of saline solution 0.9% will be instilled on the ocular surface. The participants will turn their eyes with eyes closed. The tear-wash fluid will be collected from the inferior fornix of the eye using a micropipette. Tear-was fluid will be placed in codified tubes stored at -150 degrees.

  • OtherSampling of aqueous humor

    Aqueous humor will be collected at the start of any of surgery for which the participant presents. A paracentesis of the anterior chamber is a common first step in intraocular surgeries. Aqueous humor is then commonly diluted with viscoelastic material injected inside the anterior chamber to avoid collapse of the anterior chamber. This way, the aqueous humor is commonly diluted or replaced entirely by the viscoelastic material injected during intraocular surgeries. A volume of 0.1 ml of aqueous humor will be taken by paracentesis using a 30-gauge needle connected to a 1-ml syringe. It consists of less than half of the total volume of aqueous humor in the eye. Aqueous humor will be placed in codified tubes stored at -80 degrees.

06

What researchers measure

Primary outcomes

  1. Concentration of inflammatory mediators in aqueous humor

    Concentration (pg/mL) of inflammatory mediators in aqueous humor measured by ELISA multiplex.

    Time frame: Baseline

  2. Concentration of inflammatory mediators in tears

    Concentration (pg/mL) of inflammatory mediators in tears measured by ELISA multiplex.

    Time frame: Baseline

  3. Correlation between tears and aqueous humor

    Correlation between the concentration of inflammatory mediators in tears and aqueous humor, determined by Spearman correlation test.

    Time frame: Baseline

Secondary outcomes

  1. Incidence of anterior structural changes

    Incidence of anterior structural changes in the eye (iris, iridocorneal angle, trabecular meshwork, cornea), evaluated by anterior segment optical coherence tomography (AS-OCT) imaging.

    Time frame: Baseline, 3 months, 6 months, 12 months

  2. Change of visual acuity through time

    Change of visual acuity at each time point compared to baseline visual acuity. The visual acuity is measured using the Snellen chart.

    Time frame: Baseline, 3 months, 6 months, 12 months

  3. Proportion of participants with visual field loss of 30% or more

    Proportion of participants with visual field loss of 30% or more at each time point, measured using the automated Humphrey 24-2 visual field. The loss of 30% or more of visual field is calculated using the baseline test as reference.

    Time frame: Baseline, 3 months, 6 months, 12 months

  4. Intraocular pressure

    Evaluation of intraocular pressure (units of mmHg) at each time point using Goldman tonometry.

    Time frame: Baseline, 3 months, 6 months, 12 months

  5. Incidence of posterior structural changes

    Incidence of posterior structural changes in the eye (optic nerve and retina), evaluated by spectral domain optical coherence tomography (SD-OCT) imaging.

    Time frame: Baseline, 3 months, 6 months, 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Szigiato AA, Bostan C, Nayman T, Harissi-Dagher M. Long-term visual outcomes of the Boston type I keratoprosthesis in Canada. Br J Ophthalmol. 2020 Nov;104(11):1601-1607. doi: 10.1136/bjophthalmol-2019-315345. Epub 2020 Feb 17. PubMed 32066560 ↗
  • Wang Q, Harissi-Dagher M. Characteristics and management of patients with Boston type 1 keratoprosthesis explantation--the University of Montreal Hospital Center experience. Am J Ophthalmol. 2014 Dec;158(6):1297-1304.e1. doi: 10.1016/j.ajo.2014.08.037. Epub 2014 Aug 28. PubMed 25174898 ↗
  • Crnej A, Paschalis EI, Salvador-Culla B, Tauber A, Drnovsek-Olup B, Shen LQ, Dohlman CH. Glaucoma progression and role of glaucoma surgery in patients with Boston keratoprosthesis. Cornea. 2014 Apr;33(4):349-54. doi: 10.1097/ICO.0000000000000067. PubMed 24531120 ↗
  • Aldave AJ, Kamal KM, Vo RC, Yu F. The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology. 2009 Apr;116(4):640-51. doi: 10.1016/j.ophtha.2008.12.058. Epub 2009 Feb 25. PubMed 19243830 ↗
  • Baltaziak M, Chew HF, Podbielski DW, Ahmed IIK. Glaucoma after corneal replacement. Surv Ophthalmol. 2018 Mar-Apr;63(2):135-148. doi: 10.1016/j.survophthal.2017.09.003. Epub 2017 Sep 18. PubMed 28923582 ↗
  • Banitt M. Evaluation and management of glaucoma after keratoprosthesis. Curr Opin Ophthalmol. 2011 Mar;22(2):133-6. doi: 10.1097/ICU.0b013e328343723d. PubMed 21191292 ↗
  • Cueva Vargas JL, Belforte N, Di Polo A. The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling. Neurobiol Dis. 2016 Sep;93:156-71. doi: 10.1016/j.nbd.2016.05.002. Epub 2016 May 6. PubMed 27163643 ↗
  • Crnej A, Omoto M, Dohlman TH, Dohlman CH, Dana R. Corneal inflammation after miniature keratoprosthesis implantation. Invest Ophthalmol Vis Sci. 2014 Dec 16;56(1):185-9. doi: 10.1167/iovs.14-15884. PubMed 25515579 ↗
  • Engel LA, Muether PS, Fauser S, Hueber A. The effect of previous surgery and topical eye drops for primary open-angle glaucoma on cytokine expression in aqueous humor. Graefes Arch Clin Exp Ophthalmol. 2014 May;252(5):791-9. doi: 10.1007/s00417-014-2607-5. Epub 2014 Mar 18. PubMed 24638257 ↗
  • Freedman J, Iserovich P. Pro-inflammatory cytokines in glaucomatous aqueous and encysted Molteno implant blebs and their relationship to pressure. Invest Ophthalmol Vis Sci. 2013 Jul 18;54(7):4851-5. doi: 10.1167/iovs.13-12274. PubMed 23788371 ↗
  • Burgos-Blasco B, Vidal-Villegas B, Saenz-Frances F, Morales-Fernandez L, Perucho-Gonzalez L, Garcia-Feijoo J, Martinez-de-la-Casa JM. Tear and aqueous humour cytokine profile in primary open-angle glaucoma. Acta Ophthalmol. 2020 Sep;98(6):e768-e772. doi: 10.1111/aos.14374. Epub 2020 Feb 11. PubMed 32043817 ↗
  • Robert MC, Arafat SN, Spurr-Michaud S, Chodosh J, Dohlman CH, Gipson IK. Tear Matrix Metalloproteinases and Myeloperoxidase Levels in Patients With Boston Keratoprosthesis Type I. Cornea. 2016 Jul;35(7):1008-14. doi: 10.1097/ICO.0000000000000893. PubMed 27191670 ↗
  • Chen KH, Wu CC, Roy S, Lee SM, Liu JH. Increased interleukin-6 in aqueous humor of neovascular glaucoma. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2627-32. PubMed 10509659 ↗
  • Hu DN, Ritch R, Liebmann J, Liu Y, Cheng B, Hu MS. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma. 2002 Oct;11(5):406-10. doi: 10.1097/00061198-200210000-00006. PubMed 12362079 ↗
  • Kuchtey J, Rezaei KA, Jaru-Ampornpan P, Sternberg P Jr, Kuchtey RW. Multiplex cytokine analysis reveals elevated concentration of interleukin-8 in glaucomatous aqueous humor. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6441-7. doi: 10.1167/iovs.10-5216. Epub 2010 Jun 30. PubMed 20592224 ↗
  • Dohlman CH, Zhou C, Lei F, Cade F, Regatieri CV, Crnej A, Dohlman JG, Shen LQ, Paschalis EI. Glaucoma After Corneal Trauma or Surgery-A Rapid, Inflammatory, IOP-Independent Pathway. Cornea. 2019 Dec;38(12):1589-1594. doi: 10.1097/ICO.0000000000002106. PubMed 31453878 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2020 (actual). Primary completion is estimated for Oct 2028, 101 months after the start.

Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 101 months is above that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Oct 2024 → Oct 2028 and completion May 2025 → May 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2020
First posted
Apr 9, 2020
StartActual
May 11, 2020
Primary completionEst.
Oct 2028was Oct 2024
CompletionEst.
May 2029was May 2025
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Centre Hospitalier de l'Université de Montréal (CHUM) · Montreal, Canada
Show 1 removed
  • Centre Hospitalier de l'Université de Montréal (CHUM) · Montréal, Canada
Oct 23, 2026
Primary completion
Oct 2024→Oct 2028
Oct 23, 2026
Study completion
May 2025→May 2029
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    1 site added, 1 site removed
    Show site
    • Centre Hospitalier de l'Université de Montréal (CHUM) · Montreal, Canada
    Show 1 removed
    • Centre Hospitalier de l'Université de Montréal (CHUM) · Montréal, Canada
    Primary completion Oct 2024→Oct 2028
    Study completion May 2025→May 2029
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04339907
Responsible party
Sponsor
First posted
Apr 9, 2020
Start date
May 11, 2020
Primary completion
Oct 2028 (estimated)
Completion
May 2029 (estimated)
Last update
Oct 23, 2026

Study contacts

Marie-Catherine Tessier, M.Sc.
Contact
marie-catherine.tessier.chum@ssss.gouv.qc.ca
1-514-890-8000 ext. 11550
Dominique Geoffrion, B.Sc.
Contact
dominique.geoffrion@mail.mcgill.ca
1-514-890-8000 ext. 11550
Younes Agoumi, MD
principal investigator · Centre hospitalier de l'Université de Montréal (CHUM)
Mona Harissi-Dagher, MD
study director · Centre hospitalier de l'Université de Montréal (CHUM)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion